Advertisement

Medical Oncology

, 36:97 | Cite as

Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production of reactive oxygen species in hepatocellular carcinoma

  • Zhilei Wang
  • Chengxin Gu
  • Xinrui Wang
  • Yating Lang
  • Yanqin Wu
  • Xiaoqin Wu
  • Xifei Zhu
  • Kunyuan WangEmail author
  • Hui YangEmail author
Original Paper
  • 69 Downloads

Abstract

The development of drug resistance affecting the prognosis of patients with hepatocellular carcinoma (HCC) leads to low survival rate of HCC patients. Caffeine is reported to have a function of protecting the liver and anti-tumor activity. Therefore, caffeine may be an ideal enhancer for HCC chemotherapy regimens. Our study showed that the combination of caffeine and 5-FU significantly inhibited the proliferation of HCC cells in vivo and in vitro comparing with caffeine or 5-FU monotherapy. The CI values of caffeine (0.5 mM) combined with 5-FU (25, 50 μM) were all less than 1, confirming that the utilization of drug combination has a synergistic inhibitory effect on the proliferation of HCC cells. Meanwhile, results of Western blot and TUNEL assays demonstrated that the apoptotic level of HCC cells in the combined group was significantly increased. The protein expression level of cleaved PARP was up-regulated, while the protein level of Bcl-2 and Bcl-xL was down-regulated. In addition, we found that ROS levels were increased in the 1 mM caffeine and 25 μM 5-FU combination group comparing with the control or single drug group. Taken together, this is the first study to demonstrate that the combination of caffeine and 5-FU inhibits HCC cells proliferation and promotes cellular apoptosis by regulating intracellular ROS production. The present data provides a basis for the application of caffeine combined with 5-FU as a novel chemotherapy regimen for HCC.

Keywords

Caffeine 5-Fluouracil Hepatocellular carcinoma Proliferation Apoptosis Reactive oxygen species 

Notes

Author contributions

ZW generated, analyzed, and interpretated the data and prepared the manuscript. CG, XW, YL, YW, XW, and XZ generated, analyzed, and interpretated the data. KW generated the idea, designed the study, analyzed and interpretated the data, and prepared the manuscript. HY generated the idea, designed the study, analyzed and interpretated the data, and edited the manuscript.

Funding

This study was supported by Grants from Guangzhou Medical University Student Science and Technology Innovation Project (Grant No. 2017A027), the Science and Technology Program of Guangzhou (Grant No. 201707010470), and the National Natural Science Foundation of China (Grant No. 81372634) and the Guangdong Natural Science Funds for Distinguished Young Scholar (Grant No. S2013050014121).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefGoogle Scholar
  2. 2.
    Finn RS, et al. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and meta-analysis. Hepatology. 2018;67(1):422–35.CrossRefGoogle Scholar
  3. 3.
    Doherty M, Smith PM. Effects of caffeine ingestion on exercise testing: a meta-analysis. Int J Sport Nutr Exerc Metab. 2004;14(6):626–46.CrossRefGoogle Scholar
  4. 4.
    McLellan TM, Caldwell JA, Lieberman HR. A review of caffeine’s effects on cognitive, physical and occupational performance. Neurosci Biobehav Rev. 2016;71:294–312.CrossRefGoogle Scholar
  5. 5.
    Holick CN, et al. Coffee, tea, caffeine intake, and risk of adult glioma in three prospective cohort studies. Cancer Epidemiol Biomark Prev. 2010;19(1):39–47.CrossRefGoogle Scholar
  6. 6.
    Cheng YC, et al. Caffeine suppresses the progression of human glioblastoma via cathepsin B and MAPK signaling pathway. J Nutr Biochem. 2016;33:63–72.CrossRefGoogle Scholar
  7. 7.
    Sartini M, et al. Coffee consumption and risk of colorectal cancer: a systematic review and meta-analysis of prospective studies. Nutrients. 2019;11(3):694.CrossRefGoogle Scholar
  8. 8.
    Oh CC, et al. Coffee, tea, caffeine, and risk of non-melanoma skin cancer in a Chinese population: the Singapore Chinese Health Study. J Am Acad Dermatol. 2019;81:395–402.CrossRefGoogle Scholar
  9. 9.
    Wiltberger G, et al. Protective effects of coffee consumption following liver transplantation for hepatocellular carcinoma in cirrhosis. Aliment Pharmacol Ther. 2019;49(6):779–88.CrossRefGoogle Scholar
  10. 10.
    Dong S, et al. Low concentration of caffeine inhibits the progression of the hepatocellular carcinoma via Akt signaling pathway. Anticancer Agents Med Chem. 2015;15(4):484–92.CrossRefGoogle Scholar
  11. 11.
    Edling CE, et al. Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. Cancer Biol Ther. 2014;15(5):524–32.CrossRefGoogle Scholar
  12. 12.
    Kawano Y, et al. Caffeine increases the antitumor effect of Cisplatin in human hepatocellular carcinoma cells. Biol Pharm Bull. 2012;35(3):400–7.CrossRefGoogle Scholar
  13. 13.
    Xia Y, et al. A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma. Radiat Oncol. 2017;12(1):47.CrossRefGoogle Scholar
  14. 14.
    Macaire P, et al. Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years. Eur J Cancer. 2019;111:116–25.CrossRefGoogle Scholar
  15. 15.
    Abdel-Rahman O. 5-Fluorouracil-related cardiotoxicity; findings from five randomized studies of 5-fluorouracil-based regimens in metastatic colorectal cancer. Clin Colorectal Cancer. 2019;18(1):58–63.CrossRefGoogle Scholar
  16. 16.
    Chen LT, et al. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: expanded analysis of a global phase 3 trial. Eur J Cancer. 2018;105:71–8.CrossRefGoogle Scholar
  17. 17.
    Wen S, et al. Nucleoside diphosphate kinase 2 confers acquired 5-fluorouracil resistance in colorectal cancer cells. Artif Cells Nanomed Biotechnol. 2018;46(sup1):896–905.CrossRefGoogle Scholar
  18. 18.
    Wang M, et al. Expression of the breast cancer resistance protein and 5-fluorouracil resistance in clinical breast cancer tissue specimens. Mol Clin Oncol. 2013;1(5):853–7.CrossRefGoogle Scholar
  19. 19.
    Jin J, et al. Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). World J Gastroenterol. 2002;8(6):1029–34.CrossRefGoogle Scholar
  20. 20.
    Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–81.CrossRefGoogle Scholar
  21. 21.
    Chen T, et al. LncRNA-uc002mbe.2 interacting with hnRNPA2B1 Mediates AKT deactivation and p21 up-regulation induced by trichostatin in liver cancer cells. Front Pharmacol. 2017;8:669.CrossRefGoogle Scholar
  22. 22.
    Noordhuis P, et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol. 2004;15(7):1025–32.CrossRefGoogle Scholar
  23. 23.
    Li JH, et al. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3970–7.CrossRefGoogle Scholar
  24. 24.
    Lee SW, et al. Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. Ther Adv Med Oncol. 2017;9(10):615–26.CrossRefGoogle Scholar
  25. 25.
    Korber MI, et al. NF-kappaB addiction and resistance to 5-fluorouracil in a multi-stage colon carcinoma model. Int J Clin Pharmacol Ther. 2013;51(1):35–7.CrossRefGoogle Scholar
  26. 26.
    Eskandari MR, et al. A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capecitabine. Xenobiotica. 2015;45(1):79–87.CrossRefGoogle Scholar
  27. 27.
    Bamia C, et al. Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer. 2015;136(8):1899–908.CrossRefGoogle Scholar
  28. 28.
    Quan HY, Kim DY, Chung SH. Caffeine attenuates lipid accumulation via activation of AMP-activated protein kinase signaling pathway in HepG2 cells. BMB Rep. 2013;46(4):207–12.CrossRefGoogle Scholar
  29. 29.
    Wang TJ, et al. Caffeine enhances radiosensitization to orthotopic transplant LM3 hepatocellular carcinoma in vivo. Cancer Sci. 2010;101(6):1440–6.CrossRefGoogle Scholar
  30. 30.
    Zou X, et al. Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway. J Pharmacol Sci. 2016;131(4):233–40.CrossRefGoogle Scholar
  31. 31.
    Hu Z, et al. Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound. J Exp Clin Cancer Res. 2016;35:71.CrossRefGoogle Scholar
  32. 32.
    Goncalves DF, et al. Caffeine and acetaminophen association: effects on mitochondrial bioenergetics. Life Sci. 2018;193:234–41.CrossRefGoogle Scholar
  33. 33.
    Zeidan-Chulia F, et al. Major components of energy drinks (caffeine, taurine, and guarana) exert cytotoxic effects on human neuronal SH-SY5Y cells by decreasing reactive oxygen species production. Oxid Med Cell Longev. 2013;2013:791795.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of GastroenterologyThe Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhouPeople’s Republic of China
  2. 2.The Second Clinical Medicine School of Guangzhou Medical UniversityGuangzhouPeople’s Republic of China

Personalised recommendations